UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase I/II trial will investigate a new CD19 directed CAR-T therapy manufactured locally with the goals to expedite infusion to wider patient inclusion that includes those who were previously excluded, such as pediatric patients with B-cell NHL and patients in primary relapse.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek od 31 dni do 30 lat
- •Diagnoza białaczki ALL lub chłoniaka NHL pochodzenia z komórek B
- •Potwierdzenie białka CD19 w badaniu laboratoryjnym
- •Zgoda rodziców lub opiekunów (pacjenci poniżej 18 lat) lub samego pacjenta
- •Gotowość do uczestnictwa w długotrwałym badaniu obserwacyjnym
- •Dla pacjentów w wieku rozrodczym: używanie skutecznej antykoncepcji przez 12 miesięcy od ostatniego podania leku
- •Możliwość pobrania i przechowywania komórek do terapii
Simplified criteria — AI translation
Trial details
- Minimum age
- 31 Days
- Maximum age
- 30 Years
- Last updated (source)
- September 14, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Children's Hospital Colorado
Aurora, United States
Trial contact
Vanessa Fabrizio, MD, MS
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/15/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.